Head of Group 2 Concurrent Post… Strengthening Global and Specialty Sectors
New Executives: Half in Their 40s, Selection of ‘Young Talent’
Samyang Group announced on the 25th that it has conducted a regular executive reshuffle and organizational restructuring, appointing Kim Kun-ho (pictured), the President of Strategy at Samyang Holding and the eldest son of Chairman Kim Yoon, as the head of the Chemical Business Group.
This marks the first personnel and organizational reshuffle since the group celebrated its 100th anniversary this year, focusing on strengthening the group’s core businesses in the ‘global’ and ‘specialty (high functionality)’ areas. To that end, Samyang Group has reorganized the Chemical Group by splitting it into ‘Chemical Group 1,’ which will include traditional chemical materials businesses, and ‘Chemical Group 2,’ which will focus on specialty businesses to improve management efficiency. Chemical Group 1 will continue to be led by the existing Chemical Group head, CEO Kang Ho-sung, while Chemical Group 2 will be headed by Kim Kun-ho, who will concurrently serve as Group Head, to drive growth in related businesses.
For the Biopharm Group, they have recruited former ST Pharm CEO Kim Kyung-jin as a new Group Head. As the newly appointed head of Samyang Holdings’ Biopharm Group, Kim is expected to focus on expanding in the global market, strengthening expertise in contract development and manufacturing (CDMO), and accelerating R&D of mRNA delivery systems. Additionally, in this reshuffle, the group appointed three of the six new internal executives from outside recruits to be in their 40s, placing them in key roles within the group.